UK Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis

UK Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis


$ 3999

UK Methicillin-resistant Staphylococcus Aureus (MRSA) drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rise in governmental and private financing for research and development of novel anti-MRSA medications as well as their improved screening are the main drivers of the growth of the market for treating methicillin-resistant staphylococcus aureus (MRSA). Some of the major key players in this market are Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., etc.

ID: IN10GBPH335 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Dr. Netal Patel

Buy Now

UK Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis Summary

UK Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is valued at around $93.2 Mn in 2022 and is projected to reach $113.7 Mn by 2030, exhibiting a CAGR of 2.52% during the forecast period 2023-2030.

Methicillin-resistant MRSA Staphylococcus aureus is one of the most prevalent infections nowadays. The primary cause of bacteremia, endocarditis, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections is the same bacterium that lives as a commensal and is spread in healthcare and community settings. The epidemiology of MRSA is principally defined by the repeated emergence of epidemic strains, despite the genetic diversity of the disease. Despite a recent decrease in occurrence in some areas, MRSA continues to pose a serious clinical hazard due to its consistently high morbidity and fatality rates. The evaluation of both novel antibiotics and ancillary parts of care, such as infectious disease consultation, echocardiography, and source control, is necessary for successful therapy, which is still difficult to achieve. The rise in governmental and private financing for research and development of novel anti-MRSA medications as well as their improved screening are the main drivers of the growth of the market for treating methicillin-resistant staphylococcus aureus (MRSA). The global major players in this market are Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.

Market Dynamics

Market Growth Drivers

MRSA infections are now a significant issue in the world of medicine. The rising incidence of MRSA infections, particularly in hospitals and healthcare settings, is driving the demand for effective drugs to treat and manage these infections. Governments and regulatory bodies from all over the world have realized how vital it is to confront antibiotic resistance and fight MRSA infections. The market for MRSA medications has benefited from the implementation of encouraging regulations, expedited approval procedures, and incentives to promote research and development in this area.

Market Restraints

New medication development is a time-consuming and expensive procedure, especially for novel antibiotics. Significant effort and money must be put into the research, preclinical testing, clinical trials, and regulatory approval phases. Pharmaceutical companies may choose not to invest in MRSA medication research & development due to the significant development costs involved. The financial cost of MRSA infections can be substantial. Treatment for MRSA infections can be quite expensive, involving hospitalisation, lab work, and long-term care. These economic concerns, particularly in healthcare systems with limited resources, can affect the cost and availability of MRSA medications.

Competitive Landscape

Key Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Allergan (now part of AbbVie Inc.)
  • Melinta Therapeutics, Inc.
  • Theravance Biopharma, Inc.
  • Nabriva Therapeutics plc.
  • Tetraphase Pharmaceuticals (now part of La Jolla Pharmaceutical Company)
  • Paratek Pharmaceuticals, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Methicillin Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation

By Drug Class

  • Oxazolidinones
  • Lipopeptides
  • Cephalosporin
  • Tetracycline
  • Folate Antagonist
  • Other Drug Classes

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up